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Bone is a highly vascularized organ, thus angiogenesis is a vital process during bone remodeling.
However, the role of vascular systems in bone remodeling is not well recognized. Here we show that
netrin-4 inhibits osteoclast differentiation in vitro and in vivo. Co-cultures of bone marrow macro-
phages with vascular endothelial cells markedly inhibited osteoclast differentiation. Adding a neu-
tralizing antibody, or RNA interference against netrin-4, restored in vitro osteoclast differentiation.
Administration of netrin-4 prevented bone loss in an osteoporosis mouse model by decreasing the
osteoclast number. We propose that vascular endothelial cells interact with bone in suppressing
bone through netrin-4.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction is vital to the skeletal development and bone remodeling [7,8].Bone is a dynamic tissue remodeled with a balance of bone for-
mation by osteoblasts and bone resorption by osteoclasts through-
out life, which is organized by several organs preferentially
through the endocrine systems [1,2] and nervous systems [3–5]
independently or simultaneously. Very recently, we showed that
the sensory nerve plays a core role in bone remodeling [6]. Vascu-
larization supplies various tissues including bone with oxygen,
nutrients, hormones and cytokines, suggesting that angiogenesisBecause the vascular systems communicate with the nervous sys-
tems [9], it is conceivable that the vascular systems indirectly and/
or directly interact with bone cells involved in bone remodeling.
Osteoclasts are the only cells which are capable of resorbing
bone [10]. Hemopoietic cells of the monocytes/macrophage lineage
differentiate into osteoclasts under the control of macrophage
colony-stimulating factor (M-CSF) and receptor activator of
nuclear factor-jB ligand (RANKL), both of which are generated
by osteoblastic cells in bone tissues [10,11]. Several reports have
indicated that vascular endothelial cells communicate with osteo-
clasts and their precursors [12]. Vascular endothelial growth factor
(VEGF) is a potent angiogenic factor that is upregulated during
osteoclast differentiation via hypoxia-inducible factor-1a [13].
Hematopoietic and endothelial cells stimulated by transforming
growth factor-b 1 express VEGF which enhance osteoclast survival
and osteoclastic bone resorption [14,15]. Endothelin-1 also
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osteoclastic bone resorption [16]. Tumor necrosis factor superfam-
ily member 18 which is produced by vascular endothelial cells
inhibits osteoclastogenesis [17], whereas endothelial progenitor
cells enhance their survival, migration and differentiation [18].
Moreover, Chikatsu et al. have recently shown that the formation
of tartrate-resistant acid phosphatase (TRAP)-positive cells was
suppressed, when bone-derived clonal endothelial cells were
separately co-cultured with bone marrow macrophages by a mem-
brane ﬁlter in a Transwell [19], suggesting that a soluble inhibitory
factor(s) of osteoclast differentiation is produced by vascular endo-
thelial cells. Inhibitory cytokines of osteoclastogenesis such as
interleukin-4 and granulocyte macrophage colony-stimulating fac-
tor were not considered to be potential candidates, because their
neutralizing antibodies could not abolish the inhibitory effect of
the formation of osteoclast-like cells in co-cultures of bone marrow
cells and vascular endothelial cells, suggesting that other unknown
humoral factors produced by endothelial cells are present.
Mammalian netrins belong to the laminin superfamily, and the
secreted proteins (netrin-1, netrin-3, netrin-4 and netrin-5) and
membrane-bound proteins (netrin-G1 and netrin-G2) are involved
in axon migration, lymphangiogenesis and vascularization [20,21].
Netrin-4 (Ntn4) induces lymphangiogenesis in vivo, whereas it
may act as a negative regulator of corneal epithelial cell prolifera-
tion and retinal branching in ocular tissues [21,22]. Moreover,
endothelial cell-derived Ntn4 supports adhesion and differentia-
tion of pancreatic epithelial cells [23].
A recent study using human samples demonstrated that Ntn4
expression is an independent predictor of improved outcome in
breast cancer [24]. However, the role of Ntn4 in bone remodeling
still remains unclear. We report here that vascular endothelial cells
communicate with BMMs in inhibiting osteoclast differentiation
through Ntn4 in vitro and administration of Ntn4 prevented bone
loss by decreasing the osteoclast number in an osteoporosis mouse
model in vivo.2. Materials and methods
2.1. Antibodies
For antibody blockade assay, anti-Ntn4 antibody (AF1132, R&D)
(at 100 ng/ml) was added to the culture medium. Normal goat IgG
(sc-45077, Santa Cruz) was used as a negative control. For immu-
noblotting, anti-Ntn4 antibody (sc-365280, Santa Cruz) and b-actin
(sc-47778, Santa Cruz) were used.
2.2. Animals
All mice (C57BL/6) were obtained from Tokyo Laboratory Ani-
mals Science, and were kept on a normal laboratory chow in an
environmentally controlled clean room at the Department of Oral
and Maxillofacial Surgery, Saitama Medical University. The exper-
iments were conducted according to the institutional guidelines
for ethical animal experiments (Admission number 1165).
2.3. Cell culture
Mouse osteoclastic cells were generated according to the estab-
lished in vitro protocols [25]. In short, bone marrow cells obtained
from tibia of 8- to 10-week-old female C57BL/6 mice were cultured
in a-minimal essential medium (MEMa) containing 10% FBS for
16–20 h, and non-adherent cells were harvested and inoculated
at 1  105 cells per cm2 for 2 days in the presence of 10 ng/ml of
M-CSF (Peprotech). Adherent cells were used as bone marrowmac-
rophages (BMMs). To obtain osteoclastic cells, BMMs were furthercultured with 100 ng/ml of RANKL (Oriental Yeast) in the presence
of 10 ng/ml of M-CSF (BMMs-RANKL cultures). We used M-CSF and
RANKL at these concentrations throughout the study. Recombinant
Ntn4 (R&D systems) was added at the same time with RANKL. After
culture for 5 days, cells were ﬁxed with 10% formalin for 5 min to
stain for TRAP. Thereafter, they were re-ﬁxed with ethanol:acetone
(50:50 v/v) for 1 min and incubated in acetate buffer (pH 4.8) con-
taining naphthol AS-MX phosphate (Sigma–Aldrich), fast red violet
LB salt (Sigma–Aldrich), and 50 mM sodium tartrate at room tem-
perature. TRAP-positive multinucleated cells with more than 3
nuclei were counted as osteoclasts. Results are representative of
more than four individual experiments. The murine vascular endo-
thelial cell line, UV$2 (UV2, RCB1994), was provided by the RIKEN
BRC through the National Bio-Resource Project of the MEXT, Japan.
UV2 cells were cultured in a-MEM containing 10% FBS. For the co-
culture without cell–cell contact, a Transwell system (0.4 lm pore
size, 12 well, Cat No. 3460, Corning) was used. After BMMs were
incubated for 2 days at 300 * 104 cells per well, UV2 was seeded
on the upper chamber at 3 * 104 cells per cm2 in the presence of
RANKL. Culture medium was replaced with fresh medium every
2–3 days. All cultures were maintained at 37 C in a humidiﬁed
air containing 5% CO2.
2.4. Reverse-transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using ISOGEN (Nippon
Gene) and was subjected to RT-PCR using a SuperScript One-Step
RT-PCR kit (Life Technologies) according to the manufacturer0s
instructions. The gene-speciﬁc primer pairs used are as follows:
Ntn4 sense, 50-GGCCTGGAAGATGATGTTGT-30 and Ntn4 antisense,
50-AATGGTGAGGTTTTGCGTTC-30; b-actin sense, 50-AGAAGGACT
CCTATGTGGGTGA-30 and b-actin antisense, 50-CATGATCTGGGT
CATCTTTTCA-30. For RT-PCR analysis, cDNA synthesis was per-
formed for 30 min at 45 C, and the products were denatured for
2 min at 94 C. PCR ampliﬁcation was carried out for 32 cycles
(denaturation for 60 s at 94 C, followed by primer annealing for
90 s at 55 C, and extension for 180 s at 72 C).
2.5. Quantitative real time RT-PCR
To validate the changes of gene expression, quantitative real
time RT-PCR (qPCR) analysis was performed with an Applied Bio-
systems Prism 7900HT Sequence Detection System according to
the manufacturer’s instructions (Life Technologies). Total RNA
was extracted from osteoclasts and UV2 using ISOGEN (Nippon
Gene). For qPCR of genes related with osteoclastic differentiation,
we used TaqMan-based detection [26]. Reverse-transcriptase reac-
tion was performed with the High Capacity RNA-to-cDNA Master
Mix (Life Technologies). PCR ampliﬁcation with real-time detection
performed with TaqMan Gene Expression Master Mix (Life Tech-
nologies). TaqMan Gene Expression Assays (Life Technologies) for
NFATc1 (Mm00479445_m1) and Cathepsin K (Mm00484039_m1)
and Mouse GAPDH (Mm03302249_g1) which was used as an
endogenous control. To assess the efﬁcacy of knockdown by si-
RNA for Ntn4, we used SYBR Green-based detection [27].
Reverse-transcriptase reaction was performed with High Capacity
cDNA Reverse Transcription kit (Life Technologies). The cDNA
was ampliﬁed by PCR using speciﬁc primers for Ntn4 and b-actin
as indicated ‘‘RT-PCR’’ methods. SYBR green-based qPCR was per-
formed using THUNDERBIRD SYBR qPCR Mix (TOYOBO). Thermal
cycling conditions comprised an initial UNG incubation at 50 C
for 2 min, AmpliTaq Gold DNA polymerase activation at 95 C for
10 min, 40 cycles of denaturing at95 C for 15 s, and annealing
and extension at 60 C for 1 min. Ampliﬁcation data were analyzed
with an Applied Biosystems Prism Sequence Detection Software
version 2.1 (Life Technologies). Values were normalized to GAPDH
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in triplicate assays.
2.6. Measurement of Ntn4 in the culture supernatants
Ntn4 protein in each supernatant of BMMs-RANKL cultures,
UV2 cultures, and the co-culture of UV2 with BMMs in the pres-
ence of M-CSF and RANKL (UV2 + BMMs-RANKL cultures), was
measured using a mouse Ntn4 ELISA kit (CUSABIO), according toB
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shown are representative of four independent experiments.the manufacturer’s instruction. Control medium was a negative
control. We analyzed six samples in each group.
2.7. Immunoblot analysis
The analysis was performed as described previously [28].
Brieﬂy, the cells were rinsed with ice-cold PBS and lysed with a
1% Triton X-100 lysis buffer (150 mM NaCl, 50 mM Tris–HCl [pH
8.0]) including protease inhibitor cocktails (Sigma–Aldrich). Thewithout
UV2
with
UV2
0
200
400
600
TR
AP
-p
os
iti
ve
ce
lls
 (p
er
 w
el
l)
###
0
0.5
1
1.5
ex
pr
es
si
on
###
Ctsk
without
UV2
with
UV2
0
400
800
1200
1600
2000
(p
g/
m
l)
###
###
###
###
ular endothelial cell line. (A) Effect of UV$2 (UV2) on osteoclast differentiation was
10 ng/ml of M-CSF and 100 ng/ml of RANKL in a Trans well system for 5 days: (left
ed. (B) Quantitative RT-PCR analysis of gene expression of markers for osteoclast
el) cathepsin K (Ctsk) without UV2 (open column), OCLs in response of M-CSF and
th UV2. (C) RT-PCR analysis of gene expression of Ntn4 by UV2. MBE, mouse brain
of Ntn4 in the supernatant of BMM cultures (BMMs-RANKL), UV2 cultures, and the
L). Scale bar, 400 lm. ###P < 0.001. Data are expressed as means ± S.E.M. The results
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10 min at 4 C. The protein content was quantiﬁed by the Bradford
method (Pierce). Equal amounts of proteins were separated by
SDS–polyacrylamide gel electrophoresis and electrotransferred to
polyvinylidene diﬂuoride membranes (BIO RAD). After the blocking
of nonspeciﬁc binding by soaking the ﬁlters in 5% skim milk
(Sigma–Aldrich), the desired proteins were immunodetected with
their respective antibodies, followed by visualization using an
ECL plus Western blotting detection system (GE Healthcare),
according to the manufacturer’s instructions. The bands were
scanned by an LAS-3000mini luminescent image analyzer (Fuji
Film). b-Actin was used as a loading control.
2.8. Small interfering RNA (siRNA) transfection
Stealth Select RNAi siRNA for Ntn4 (MSS226595: TAAAGTCCAC-
CAAACTGAAGATCTT, MSS226596: CCACCTTTCACTCGATGCACAAT-
AA, MSS226597: GCTCCTAACGAATGCAGAACTTGCA) and StealthFig. 2. Inhibition of osteoclast differentiation of BMMs by Ntn4. (A) Effect of Ntn4 (0.5 l
(right panel) number of TRAP-positive multinucleated cells formed. (B) Quantitative RT-P
the presence of RANKL and recombinant Ntn4 (0.5 lg/ml or 2 lg/ml): (left panel) NFATc1,
control. Scale bar, 400 lm. #P < 0.05; ###P < 0.001. Data are expressed as means ± S.E.M.RNAi Negative Control Duplex (Low GC, Medium GC) as si-control
(si-CRL) were purchased from Life Technologies. They were all
transfected with Lipofectamine RNAi MAX (Life Technologies)
according to the manufacturer’s instructions into UV2. UV2 was
inoculated to the upper chamber of the Transwell system at 48 h
after transfection. Results were representative of more than four
individual experiments.
2.9. A mouse model of RANKL-induced osteoporosis
To obtain a mouse model of RANKL-induced osteoporosis, solu-
ble RANKL (sRANKL, 1 mg/kg) or PBS was injected intraperitoneally
at 24 h intervals for 3 days into male mice (7-week-old) as previ-
ously described. To evaluate the prophylactic effect of Ntn4, Ntn4
(1 mg/kg) or PBS was injected before each injection of sRANKL
three times at 24 h intervals intraperitoneally. The mice were
killed 90 min after the last injection. Since we have previously
shown that bisphosphonates prevent bone loss in RANKL-inducedg/ml or 2 lg/ml) on osteoclast differentiation of BMMs: (left panel) TRAP staining,
CR analysis of gene expression of markers for osteoclast differentiation by BMMs in
(right panel) Ctsk. (C) Effect of Ntn4 (2 lg/ml) on cell proliferation in BMMs cultures.
The results shown are representative of four independent experiments.
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positive control subcutaneously. Six mice were used in each group
(PBS, RANKL with PBS, RANKL with Ntn4 and RANKL with Zol).
2.10. Histological and histomorphometric analyses
RANKL-inducedmicewere injectedwith calcein (25 mg per kg of
body weight; Sigma) intraperitoneally 5 and 2 days before sacriﬁce.
After vertebrae were ﬁxed in 4% paraformaldehyde and dehydrated
by ethanol, theywere embedded inmethylmethacrylate. The plastic
blocks were trimmed and 4 or 7-lm thick sections were prepared
with a RM2255 (Leica Microsystems). Undecalciﬁed sections of the
lumbar vertebrae were stained for von Kossa, Toluidine Blue and
TRAP staining, as previously described [6]. Static and dynamic histo-
morphometric analyses were performed using OsteoMeasure Anal-
ysis System (OsteoMetrics) following nomenclature deﬁned by the
American Society for Bone and Mineral Research. Bone volume/tis-
sue volume (BV/TV; %), bone formation rate/bone surface (BFR/BS;
lm3 mm1 yr1), mineral apposition rate (MAR; mm yr1), osteo-
blast surface (Ob.S/BS; %) and osteoclast number/bone perimeter
(No.Oc/B.Pm; per 100 mm) were analysed. Six mice were examined
for each group.
2.11. Statistical analysis
Comparisons between two groups were analyzed using Stu-
dent’s t-tests and comparisons among three groups were analyzed
using One-Way Analysis of Variance and Bonferroni/Dunn meth-
ods (#P < 0.05; ##P < 0.01; ###P < 0.001). All values are represented
as the mean ± S.E.M. Results are representative examples of more
than three independent sets of experiments.Fig. 3. Ntn4 derived from vascular endothelial cells inhibits osteoclast differenti-
ation in the co-culture. (A) Effect of anti-Ntn4 antibodies (100 ng/ml) on osteoclast
differentiation in the co-culture of UV2 and BMM in the presence of M-CSF and
RANKL in a Transwell system for 5 days: (upper panel) TRAP staining, (lower panel)
number of TRAP-positive multinucleated cells formed in the co-culture of BMMs
and UV2. (B) Effect of RNA interference to Ntn4 (MSS226597) in UV2 co-cultured
with BMMs in the presence of M-CSF and RANKL on osteoclast differentiation:
(upper panel) TRAP staining, (lower panel) number of TRAP-positive multinucleated
cells formed. si-control (si-CRL), Stealth RNAi Negative Control Duplex; si-Ntn4,
siRNA to Ntn4; IgG, immunoglobulin G. Scale bar, 400 lm. ###P < 0.001. Data are
expressed as means ± S.E.M. The results shown are representative of four indepen-
dent experiments.3. Results
3.1. Osteoclast differentiation is inhibited in the co-culture of BMMs
and UV2 without cell–cell contact
Since Chikatsu et al. have demonstrated that vascular endothe-
lial cells inhibit osteoclastogenesis in the co-culture with BMMs
without cell–cell contact [19], we investigated whether the murine
vascular endothelial cell line, UV2, is also capable of inhibiting
osteoclastogenesis in the same system. Expectedly, RANKL-induced
TRAP-positive cell formation was markedly suppressed in the co-
culture of BMMs and UV2 in a Transwell, when compared without
UV2 in the co-culture (Fig. 1A). We also found that the gene expres-
sion of osteoclast differentiation markers (NFATc1 and Ctsk) was
signiﬁcantly downregulated in the Transwell co-culture system
(Fig. 1B). These results suggest that a soluble factor(s) released from
vascular endothelial cells inhibits osteoclast differentiation.
Then we focused on Ntn4 because Ntn4 has been known to be a
potent accelerator of neovascularization in vivo [29,30]. Since vas-
cular endothelial cells express Ntn4 mRNA [23,31], we examined
whether UV2 also expresses Ntn4 mRNA. We performed RT-PCR
to detect mRNA expression of Ntn4 in UV2 in comparison with
mouse brain extracts (MBE) as a positive control. MBE and spleen
cells showed moderate expression levels of Ntn4 mRNA, but white
adipose tissue (WAT) and BMMs did not. UV2 robustly expressed
Ntn4 mRNA (Fig. 1C).
We next examined whether Ntn4 protein expresses as a soluble
factor. We performed ELISA assay for Ntn4 in the supernatants of
BMMs-RANKL cultures, UV2 cultures, and UV2 + BMMs-RANKL
cultures. We found that the concentration of Ntn4 in both UV2 cul-
tures and UV2 + BMMs-RANKL cultures was much higher than that
in BMMs-RANKL cultures, indicating that Ntn4 protein is produced
as a soluble factor (Fig. 1D). The supernatant of BMMs-RANKLcultures did not contain any appreciable amounts of Ntn4
(Fig. 1D). In line with this, BMMs-RANKL cultures did not express
Ntn4 mRNA (Supplementary Fig. 1).
3.2. Ntn4 inhibits osteoclast differentiation in vitro
We examined whether Ntn4 affects osteoclast differentiation
in vitro. Recombinant Ntn4 was added to the BMMs-RANKL cul-
tures. Cultures were conducted for 5 days in the presence of
RANKL and M-CSF. TRAP-positive cell formation was signiﬁcantly
decreased in a dose-dependent manner by adding Ntn4 (Fig. 2A).
Expression of both NFATc1 and Ctsk genes was signiﬁcantly
downregulated by Nnt4 (Fig. 2B), indicating that the inhibitory
effect of endothelial cells in osteoclast differentiation is repro-
duced by adding Ntn4. To conﬁrm that the decrease of TRAP-
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eration, we assessed whether Ntn4 affect cell proliferation in
BMMs cultures. Ntn4 did not affect cell proliferation at all in
BMMs cultures (Fig. 2C).
3.3. Ntn4 released from UV2 inhibits osteoclast differentiation
We hypothesized that Ntn4 released from vascular endothelial
cells, may be a candidate for inhibiting osteoclast differentiation.
To prove this hypothesis, we conducted the ligand blockade assay
by using speciﬁc antibodies against Ntn4. Neutralizing anti-Ntn4
greatly increased osteoclast formation in the co-culture (Fig. 3A).
To examine further that Ntn4 produced by UV2 is involved in the
inhibition of osteoclast formation, we engineered expressing small
interfering RNA against Ntn4 in UV2. RNA interference-mediated
knockdown of Ntn4 in UV2 enhanced TRAP-positive cell formationFig. 4. Bone resorption is blocked by Ntn4 in vivo. Histomorphometric analyses of mice
RANKL with Zol (100 lg/kg) (n = 6). (A) (left panel) von Kossa staining of mouse vertebr
perimeter (No.Oc/B.Pm; per 100 mm). (C) Osteoblast surface (Ob.S/BS; %). (D) Bone forma
mm yr1). #P < 0.05; ###P < 0.001. Data are expressed as means ± S.E.M.in the co-culture (Fig. 3B). As seen in Supplementary Fig. 2, we con-
ﬁrmed that the efﬁcacy of gene knockdown by each si-Ntn4 in UV2
was almost 50  90% by quantitative PCR analysis and Ntn4
expression in UV2 was downregulated, when compared with the
control by immunoblot analysis.
3.4. Ntn4 prevents bone loss in RANKL-induced osteoporosis model
mice
Finally, we examined whether in vivo administration of Ntn4
improves bone loss in an osteoporosis mouse model induced by
RANKL. Injections of soluble RANKL (1 mg/kg) three times at 24 h
intervals induced bone loss in 7-week-old male mice (Fig. 4A). To
evaluate the prophylactic effect of Ntn4, Ntn4 (1 mg/kg), PBS, or
Zol (100 lg/kg) was injected intraperitoneally as a negative or a
positive control before each injection of soluble RANKL at 24 hinjected PBS (n = 6), RANKL with PBS (n = 6), RANKL with Ntn4 (1 mg/kg) (n = 6), or
a, (right panel) bone volume/tissue volume (BV/TV; %). (B) Osteoclast number/bone
tion rate/bone surface (BFR/BS; lm3 mm1 yr1). (E) Mineral apposition rate (MAR;
2268 Y. Enoki et al. / FEBS Letters 588 (2014) 2262–2269intervals. Ntn4 administration prevented bone loss by inhibiting
osteoclastic bone resorption (Fig. 4A and B). Markers for bone for-
mation like Ob.S/BS, MAR and BMF/BS did not change by Ntn4
administration. (Fig. 4C–E), indicating that the prophylactic effect
of Ntn4 in maintaining bone mass is not due to the enhancement
of bone formation.
4. Discussion
The netrin family is essential for axon guidance and vascular
development [20], while little is known in the role of netrins in
bone metabolism. In this study, we clearly showed that vascular
endothelial cells inhibit osteoclast differentiation via Ntn4. Ntn4
greatly suppressed TRAP-positive cell formation in the cultures of
BMMs upon RANKL stimulation.
Ntn4 is a strong candidate released from vascular endothelial
cells for inhibiting RANKL-induced osteoclast formation. This
notion is supported by the following four reasons. First, adding
Ntn4 to the BMMs cultures in the presence of RANKL and M-CSF
suppressed osteoclast formation in vitro. Second, adding anti-
Ntn4 recovered the suppression of RANKL-induced TRAP-positive
cell formation by vascular endothelial cells in vitro. Third, siRNA
for Ntn4 recovered the suppression of RANKL-induced TRAP-posi-
tive cell formation by vascular endothelial cells in vitro. Fourth,
administration of Ntn4 prevented bone loss in RANKL-induced
osteoporosis mouse model by decreasing osteoclast numbers
in vivo. Ntn4 released from vascular endothelial cells appears to
be involved in the inhibition of RANKL-induced osteoclast
differentiation.
Netrin receptors are known as Deleted in Colorectal Cancer
(DCC), neogenin (Neo1), adenosine A2b receptor (Adora2b), unco-
ordinated 5a, 5b, 5c, and 5d (Unc 5a, b, c, and d), and Down’s syn-
drome cell adhesion molecule (DSCAM) [20]. DCC and Unc5a,
originally discovered as receptors forNtn1, are also known as
receptors for Ntn4 [32,30]. On the other hand, Ntn4 has a proangi-
ogenic effect via an undetermined receptor, besides Unc5 recep-
tors, Adora2b, DCC and Neo1 [29]. The role of DSCAM has not
been tested before. It is therefore conceivable that DCC, Unc5a or
DSCAM, solely or in combination, is associated with the inhibitory
receptor for osteoclast differentiation by Ntn4.
Blood vessels invade into trabecular bone within epiphysis, car-
tilage-subchondral bone interface, trabecular bone within diaphy-
sis and cortical bone, suggesting that vascularization is essential
for all regions of bone [12], Why do blood vessels need to inhibit
osteoclastogenesis? Once bone is damaged or loaded by a variety
of mechanical stress, various cells inside the compartment of bone
remodeling are considered to be under a stressful condition. For
instance, RANKL expression is upregulated by mechanical loading
in osteoblasts and Ntn4 in endothelial cells is overproduced after
cerebral ischemia [30]. We hypothesize that osteoclast precursors
are stimulated by RANKL derived from osteoblasts, leading to
osteoclast differentiation, whereas vascular endothelial cells pro-
duce Ntn4 to inhibit osteoclast differentiation under pathophysio-
logical conditions such as bone fracture or overloading. Vascular
endothelial cells in bone tissues have various unique features.
Streeten et al. have demonstrated that endothelial cells derived
from bovine bone marrow have characteristic features, in which
bone marrow respond to parathyroid hormone, whereas pulmon-
ary artery do not [33].
We have shown that Ntn4 prevented bone loss in RANKL-
induced osteoporosis mouse model by decreasing osteoclast num-
bers. This in vivo data is consistent with the in vitro data that Ntn4
inhibits osteoclast differentiation. Importantly, Ntn4 also promotes
neovascularization in vivo [29]. These results suggest that Ntn4 is
an useful target molecule as a therapeutic drug for the treatment ofbone diseases such as osteoporosis and periodontitis to reconstruct
the blood vessels and bone structures.
In conclusion, the present study provides in vitro and in vivo
evidence that vascular endothelial cells inhibit osteoclast differen-
tiation via secreted factors. Such a soluble factor produced by vas-
cular endothelial cells is Ntn4, and it communicates with bone cells
in regulating bone remodeling. Ntn4 appears to work as a promis-
ing prophylactic agent for osteopenic diseases. Vascular systems
undoubtedly contribute to the regulation of bone remodeling. Fur-
ther experiments are needed to elucidate the precise mechanisms
of the interaction between blood vessels and bone tissues.
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